| Lead-Like | Fragment-Like | Drug-Like | All | Shards | |
|---|---|---|---|---|---|
| Standard Size Updated | Lead-Like 4,554,059 2012-02-06 | Fragment-Like 562,227 2012-02-03 | Drug-Like 14,322,885 2012-01-12 | All Purchasable 19,734,523 2012-01-12 | Shards 52,189 2012-02-02 |
| Clean Size Updated | Clean Leads 2,889,548 2012-02-20 | Clean Fragments 343,652 2012-02-15 | Clean Drug-Like 9,542,593 2012-02-21 | All Clean 10,538,921 2012-02-21 | Clean Shards 20,125 2011-12-15 |
| In Stock Size Updated | Leads Now 1,845,476 2012-02-05 | Frags Now 385,125 2012-02-03 | Drugs Now 6,192,930 2012-02-14 | All Now 8,545,576 2012-02-09 | Shards Now 48,388 2012-02-07 |
Comments/Citation |
Teague, Davis, Leeson, Oprea, Angew Chem Int Ed Engl. 1999 Dec 16;38(24):3743-3748.
|
Carr RA, Congreve M, Murray CW, Rees DC, Drug Discov Today. 2005 Jul 15;10(14):987
|
Lipinski, J Pharmacol Toxicol Methods. 2000 Jul-Aug;44(1):235-49.
|
Purchasable chemical space
|
Type I binding sites
|
Filtering Critieria |
(p.xlogp < 3.5 and p.mwt < 350 and p.rb <= 7) and not (p.xlogp <=2.5 and p.mwt <=250 and p.rb <= 5)
|
p.xlogp <=3.5 and p.mwt <=250 and p.rb <= 5
|
p.xlogp <= 5 and p.mwt <= 500 and p.mwt > 150 and p.rb < 8 and p.psa < 150 and p.n_h_acceptors <= 10
|
|
p.mwt < 160
|